Your browser doesn't support javascript.
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia.
Aggarwal, Anupriya; Stella, Alberto Ospina; Walker, Gregory; Akerman, Anouschka; Esneau, Camille; Milogiannakis, Vanessa; Burnett, Deborah L; McAllery, Samantha; Silva, Mariana Ruiz; Lu, Yonghui; Foster, Charles S P; Brilot, Fabienne; Pillay, Aleha; Van Hal, Sabastiaan; Mathivanan, Vennila; Fichter, Christina; Kindinger, Andrea; Hoppe, Alexandra Carey; Munier, Mee Ling; Amatayakul-Chantler, Supavadee; Roth, Nathan; Coppola, Germano; Symonds, Geoff P; Schofield, Peter; Jackson, Jennifer; Lenthall, Helen; Henry, Jake Y; Mazigi, Ohan; Jäck, Hans-Martin; Davenport, Miles P; Darley, David R; Matthews, Gail V; Khoury, David S; Cromer, Deborah; Goodnow, Christopher C; Christ, Daniel; Robosa, Roselle; Starck, Damien J; Bartlett, Nathan W; Rawlinson, William D; Kelleher, Anthony D; Turville, Stuart G.
  • Aggarwal A; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Stella AO; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Walker G; Serology and Virology Division (SAViD), NSW Health Pathology, Sydney, New South Wales, Australia.
  • Akerman A; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Esneau C; Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.
  • Milogiannakis V; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Burnett DL; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • McAllery S; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Silva MR; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Lu Y; Serology and Virology Division (SAViD), NSW Health Pathology, Sydney, New South Wales, Australia.
  • Foster CSP; Serology and Virology Division (SAViD), NSW Health Pathology, Sydney, New South Wales, Australia.
  • Brilot F; Brain Autoimmunity Group, Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, School of Medical Sciences, Sydney University of Sydney, Sydney Institute for Infectious Diseases, Sydney, New South Wales, Australia.
  • Pillay A; Brain Autoimmunity Group, Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, School of Medical Sciences, Sydney University of Sydney, Sydney Institute for Infectious Diseases, Sydney, New South Wales, Australia.
  • Van Hal S; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Mathivanan V; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Fichter C; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Kindinger A; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Hoppe AC; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Munier ML; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Amatayakul-Chantler S; Department of Bioanalytical Sciences, Plasma Product Development, Research and Development, CSL Behring, Broadmeadows, Melbourne, Victoria, Australia.
  • Roth N; Department of Bioanalytical Sciences, Plasma Product Development, Research and Development, CSL Behring AG, Bern, Switzerland.
  • Coppola G; Department of Bioanalytical Sciences, Plasma Product Development, Research and Development, CSL Behring, Broadmeadows, Melbourne, Victoria, Australia.
  • Symonds GP; Gene Therapy Research, Sydney, New South Wales, Australia.
  • Schofield P; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Jackson J; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Lenthall H; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Henry JY; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Mazigi O; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Jäck HM; University of Erlangen-Nürnberg, Erlangen, Germany.
  • Davenport MP; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Darley DR; St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Matthews GV; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Khoury DS; St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Cromer D; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Goodnow CC; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Christ D; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Robosa R; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Starck DJ; Molecular Diagnostic Medicine Laboratory, Sydpath, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Bartlett NW; Molecular Diagnostic Medicine Laboratory, Sydpath, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • Rawlinson WD; Serology and Virology Division (SAViD), NSW Health Pathology, Sydney, New South Wales, Australia.
  • Kelleher AD; Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia.
  • Turville SG; The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Nat Microbiol ; 7(6): 896-908, 2022 06.
Article in English | MEDLINE | ID: covidwho-1873507
ABSTRACT
Genetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using primary remnant diagnostic swabs. This, combined with quarantine testing and genomics surveillance, enabled the rapid isolation and characterization of all major SARS-CoV-2 variants circulating in Australia in 2021. Our platform facilitated viral variant isolation, rapid resolution of variant fitness using nasopharyngeal swabs and ranking of evasion of neutralizing antibodies. In late 2021, variant of concern Omicron (B1.1.529) emerged. Using our platform, we detected and characterized SARS-CoV-2 VOC Omicron. We show that Omicron effectively evades neutralization antibodies and has a different entry route that is TMPRSS2-independent. Our low-cost platform is available to all and can detect all variants of SARS-CoV-2 studied so far, with the main limitation being that our platform still requires appropriate biocontainment.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study Topics: Long Covid / Variants Limits: Humans Country/Region as subject: Oceania Language: English Journal: Nat Microbiol Year: 2022 Document Type: Article Affiliation country: S41564-022-01135-7

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study Topics: Long Covid / Variants Limits: Humans Country/Region as subject: Oceania Language: English Journal: Nat Microbiol Year: 2022 Document Type: Article Affiliation country: S41564-022-01135-7